ViiV Healthcare announces authorisation of Europe’s first long-acting HIV injection
December 21, 2020Sales and Marketing GlaxoSmithKline, HIV, ViiV
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline, has announced the authorisation of Europe’s first complete long-acting …
Ionis founder Stanley T Crooke to retire
December 18, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Ionis Pharmaceuticals has announced that its founder, Dr Stanley T Crooke, will retire from the company and its board of …
Sage Therapeutics appoints Barry Greene as CEO
December 18, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Sage Therapeutics, a biopharmaceutical company focused on developing treatments for central nervous system disorders, has appointed Barry Greene as Chief …
NICE recommends GSK’s Nucala for more asthma patients
December 18, 2020Medical Communications GlaxoSmithKline, NICE, asthma, mepolizumab
NICE has today published final draft guidance recommending GlaxoSmithKline’s Nucala (mepolizumab) as an add-on treatment option for severe refractory eosinophilic …
Top Ten most popular articles on Pharmafile.com this week
December 18, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Vaccine, antibody
The top news stories of the past week continue to centre around the COVID-19 pandemic; a new variant of the …
Regeneron announces initial clinical data for COVID-19 antibody cocktail
December 18, 2020Medical Communications COVID-19, Regeneron, antibody
Regeneron Pharmaceuticals has announced that initial clinical data published in the New England Journal of Medicine shows that its antibody …
Ena Respiratory’s nasal spray reduces COVID-19 replication by 96%
December 18, 2020Medical Communications COVID-19, Nasal Spray
Australian biotech Ena Respiratory has revealed that its self-administered nasal spray INNA-051, when taken once or twice weekly, reduced viral …
Biogen agrees to pay $22m to settle kickback allegations
December 18, 2020Medical Communications Biogen, multiple sclerosis
Biogen has agreed to pay $22 million to put an end to an investigation into claims that it illegally used …
Samsung Biologics names John Rim as CEO and President
December 17, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Samsung BioLogics
Samsung Biologics has appointed John Rim as the company’s President and CEO. The appointment was made effective immediately and formalised via the …
Pharmafile.com’s weekly COVID-19 news round-up
December 17, 2020Developments in the race to vaccinate against COVID-19 have dominated the news this week; a vaccine roll-out is underway in …
European approval for Kite’s CAR-T therapy Tecartus in elapsed or refractory mantle cell lymphoma
December 17, 2020Sales and Marketing CAR-T, Europe, Gilead, Kite, Tecartus
Gilead-owned Kite Therapeutics has secured marketing authorisation from the European Commission for its chimeric antigen receptor (CAR) T cell therapy …
Novavax secures deal with New Zealand for 10.7m doses of COVID-19 vaccine
December 17, 2020Sales and Marketing COVID-19, Novavax, Vaccine
Novavax has announced an Advance Purchase Agreement with New Zealand for the purchase of 10.7 million doses of NVX-CoV2373, the …
FDA says Pfizer vaccine vials contain extra doses, boosting US supply
December 17, 2020Sales and Marketing COVID-19, FDA, Pfizer, Vaccine
The FDA has announced that extra doses contained in Pfizer COVID-19 vaccine vials could expand America’s supply of the jab …
Novartis acquires Cadent Therapeutics in potential $770 million deal
December 17, 2020Sales and Marketing Cadent, Novartis, acquisition
Novartis has sealed an agreement with Cadent Therapeutics to acquire the firm in a deal worth up to $770 million, …
NICE recommends Novartis’ Beovu for wet age-related macular degeneration
December 16, 2020Research and Development NICE, Novartis, wet AMD Beovu
NICE has published its final appraisal of Novartis’ Beovu (brolucizumab), recommending that the drug be made available via the NHS …
Quarter of the world may not access COVID-19 vaccine until 2022
December 16, 2020Research and Development COVID-19, Vaccine
Almost a quarter of the world’s population may not have access to a COVID-19 vaccine until 2022, according to a …
AbbVie buys COVID-19 antibody licence from Harbour BioMed
December 16, 2020Research and Development AbbVie, COVID-19, Harbour BioMed, antibody
Harbour BioMed (HBM) and Utrecht University (UU) have announced that their fully human, SARS-CoV-2 neutralising antibody 47D11 and programme, has …
FDA panel backs Novartis’ Entresto for different form of heart disease
December 16, 2020Research and Development FDA, Novartis, heart failure
Novartis’ heart failure drug Entresto has received recommendation from the FDA’s Cardiovascular and Renal Drugs Advisory Committee for use in …
Eli Lilly scoops up gene therapy specialist Prevail Therapeutics for a potential $1.04bn
December 16, 2020Research and Development, Sales and Marketing Eli Lilly, Prevail, acquisition
Eli Lilly has struck a deal to acquire Prevail Therapeutics in a transaction that could be valued at up to …
How COVID-19 is affecting diabetics and their access to insulin in America
December 15, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Diabetic patients face daily challenges of treatment access and treatment management, so 2020 has been a particularly challenging year. Conor …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
